Related Experiment Videos
Suppressive effect of camostat mesilate (FOY 305) on acute experimental allergic encephalomyelitis (EAE)
Abstract:
Camostat mesilate (FOY305), a synthetic serine protease inhibitor and has been developed as a drug for pancreatitis, is effective in suppressing acute experimental allergic encephalomyelitis in Lewis rats. Loss of weight, clinical score and yield of myelin protein from brain stem were improved by daily injection of FOY305 compared with saline from day 6 after inoculation with homogenate of guinea pig spinal cord. A significant decrease of yield of myelin has been shown here for the first time in acute EAE in Lewis rat. This is in accord with myelin breakdown demonstrated morphologically. Our study also demonstrates a significant improvement of yield of myelin protein by FOY305. Our results suggest the possibility of a clinical application of this protease inhibitor for human demyelinating diseases such as multiple sclerosis.
Insights
Camostat mesilate, a serine protease inhibitor, improved outcomes in rats with experimental allergic encephalomyelitis (EAE). This suggests potential for treating human demyelinating diseases like multiple sclerosis.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Acute experimental allergic encephalomyelitis (EAE) is an animal model for demyelinating diseases.
- Serine protease inhibitors have shown potential in modulating immune responses.
Purpose of the Study:
- To investigate the efficacy of camostat mesilate (FOY305) in a rat model of EAE.
- To determine if FOY305 can mitigate myelin damage and improve clinical outcomes in EAE.
Main Methods:
- Lewis rats were induced with EAE using guinea pig spinal cord homogenate.
- Rats received daily injections of camostat mesilate (FOY305) or saline.
- Clinical scores, weight loss, and myelin protein yield were assessed.
Main Results:
- Camostat mesilate significantly improved clinical scores and reduced weight loss in EAE rats.
- A notable decrease in myelin protein yield was observed in EAE rats, indicating myelin breakdown.
- FOY305 treatment led to a significant improvement in myelin protein yield.
Conclusions:
- Camostat mesilate demonstrates therapeutic potential in suppressing EAE.
- The findings suggest FOY305 may be a viable treatment for human demyelinating diseases, including multiple sclerosis.